Archives
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
The Notch cleavage efficiency of Aph aS containing complexes
2022-09-21

The Notch-cleavage efficiency of Aph1aS containing complexes was lower than that of Aph1aL γ-secretases, especially in combination with PS2, suggesting that Aph1aS is a determinant of low Notch-cleavage specificity, considering that the different subcellular localization of PS1 and PS2 didn't affect
-
br Conflict of interest br Acknowledgments
2022-09-21

Conflict of interest Acknowledgments The research was funded by the Major Programs of Pharmaceutical research project of Jiangsu Province (Q2018044). Introduction Lipids are important regulators of cell death. In mammalian cells, both apoptotic and non-apoptotic cell death pathways can be
-
To meet the requirement of ferroptosis based
2022-09-21

To meet the requirement of ferroptosis-based therapy, a couple of small molecule drugs and nanomaterials were introduced to the design of ferroptosis inducers, separately. As we know, iron is a key regulator of ferroptosis. When small molecule drugs are employed to induce ferroptosis, the endogenous
-
br Materials and methods br Results br Discussion Accurate
2022-09-20

Materials and methods Results Discussion Accurate HER2 assessment for patients with invasive breast cancer is crucial to determining which patients may benefit from HER2-targeted therapy. The most recent ASCO/CAP guidelines have again redefined HER2 gene amplification as determined by dual-
-
HO acted as an intracellular defender against oxidative stre
2022-09-20

HO-1 acted as an intracellular defender against oxidative stress-induced cell damage. To elucidate the effects of HO-1 in ropivacaine-induced cytotoxicity in neuronal cells, HO-1 activity was inhibited using a specific HO-1 inhibitor zinc protoporphyrin, ZnPP. Our results indicate that ZnPP treatmen
-
Cells undergoing EMT display a downregulation of
2022-09-20

Cells undergoing EMT display a downregulation of E-cadherin and dissociation of their junctional complexes that associates cell-cell contacts with the SB 258719 hydrochloride sale cytoskeleton, known as the adherens junction (Berx and van Roy, 2009, Birchmeier and Behrens, 1994). Adherens junctions
-
Fibronectin protein level was not affected
2022-09-20

Fibronectin protein level was not affected by DIF-1, although fibronectin has also been considered a canonical Wnt signaling pathway target gene product [39]. Thus, the canonical Wnt signaling pathway may not be critical for the regulation of the expression of fibronectin in malignant melanoma cells
-
br Materials and methods br Results br Discussion According
2022-09-20

Materials and methods Results Discussion According to the literature, zaprinast is a high-affinity agonist of GPR35 (Berlinguer-Palmini et al., 2013, Divorty et al., 2015, Taniguchi et al., 2006, Zhao et al., 2010). GPR35 daunorubicin receptor has been identified within discrete regions of
-
In addition to their functional activation of GPR A
2022-09-20

In addition to their functional activation of GPR109A, compounds of the pyrazolopyrimidine class also enhanced the binding of nicotinic Oxamic acid receptor to the receptor. For instance, increased the binding of H-nicotinic acid to the receptor (black curve) in a concentration-dependent manner, w
-
To test our refinement protocol we considered a benchmark
2022-09-19

To test our refinement protocol, we considered a benchmark set of 12 N-linked glycan-containing protein structures determined by X-ray crystallography at resolutions ranging between 1.9 Å and 3.5 Å and comprising a total of 133 glycan units. We identified four incorrect anomeric configurations and 2
-
The energy required to drive the functional process to activ
2022-09-17

The energy required to drive the functional process to actively maintain lens transparency is primarily derived from the metabolism of glucose. Since the lens is avascular and exists in an environment of low oxygen tension, glucose is primarily metabolized by MS436 glycolysis (Kinoshita, 1965). This
-
MRcKO mice showed a comparable degree of
2022-09-17

MRcKO mice showed a comparable degree of cardiac remodeling compared to control (MRf/f) mice. Moreover, the worse cardiac remodeling in pressure-overloaded GRcKO mice is not due to compensatory activation of cardiomyocyte MR, because GRMRdcKO mice displayed cardiac remodeling to the same extent as G
-
Phylogenetic analysis of the secretin like hormones yields p
2022-09-17

Phylogenetic analysis of the secretin-like hormones yields poorly supported trees due to the short length of their peptide sequences (Dores et al., 1996). However, phylogenetic analyses typically show that the secretin-like peptides encoded by the proglucagon (glucagon, GLP-1 and GLP-2) and GIP Deco
-
Fpr which belongs the family of the formyl
2022-09-17

Fpr1, which belongs the family of the formyl peptide receptors with FPRL1 and FPRL2, is the principal receptor for formylated peptides which prototype is the tri-peptide fMLF. Fpr1 is highly expressed on neutrophils and macrophages [6,30], promotes their migration into the mucosa and lumen in respon
-
Lenvatinib is an orally available multi
2022-09-17

Lenvatinib is an orally available, multi-targeted tyrosine kinase inhibitor against VEGFR1–3, FGFR1–4, PDGFRα, RET, and KIT [11,12]. In a recent phase III trial for patients with previously untreated uHCC (REFLECT study), lenvatinib showed statistical non-inferiority of overall survival compared to
16598 records 414/1107 page Previous Next First page 上5页 411412413414415 下5页 Last page